Inventor
LI YUE-SHENG
US32 patents
⚠️ This page may combine multiple inventors who share the name “LI YUE-SHENG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AMGEN INC
14 patentsUS8034770B2Oct 11, 2011
FGF21 polypeptides comprising two or more mutations
AMGEN INC63 citations99
US8361963B2Jan 29, 2013
Uses of FGF21 polypeptides comprising two or more mutations
AMGEN INC64 citations98
US9273106B2Mar 1, 2016
FGF mutants with reduced proteolysis and aggregation
AMGEN INC9 citations92
US7790859B2Sep 7, 2010
Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
AMGEN INC24 citations92
US11072640B2Jul 27, 2021
Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
AMGEN INC3 citations84
US10011642B2Jul 3, 2018
Methods of treating of diabetes and obesity using FGF21 mutants
AMGEN INC4 citations84
US9493530B2Nov 15, 2016
FGF21 mutants comprising a mutation at position 98, 171 and/or 180
AMGEN INC10 citations84
US10308704B2Jun 4, 2019
Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereof
AMGEN INC12 citations83
US9562108B2Feb 7, 2017
Carrier immunoglobulins
AMGEN INC8 citations83
US8906371B2Dec 9, 2014
Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
AMGEN INC3 citations73
US11840558B2Dec 12, 2023
Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
AMGEN INC0 citations62
US11685770B2Jun 27, 2023
Stabilized receptor polypeptides and uses thereof
AMGEN INC0 citations62
US9562107B2Feb 7, 2017
Carrier immunoglobulins
AMGEN INC1 citations61
US10189912B2Jan 29, 2019
Carrier immunoglobulins
AMGEN INC0 citations50
BELOUSKI EDWARD JOHN
6 patentsUS8835385B2Sep 16, 2014
FGF21 polypeptides comprising two or more mutations and uses thereof
BELOUSKI EDWARD JOHN48 citations97
US8795985B2Aug 5, 2014
FGF 21 polypeptides comprising two or more mutations and uses thereof
BELOUSKI EDWARD JOHN48 citations97
US8642546B2Feb 4, 2014
FGF21 mutant fusion polypeptides and uses thereof
BELOUSKI EDWARD JOHN64 citations97
US8618053B2Dec 31, 2013
FGF21 mutants multimers and uses thereof
BELOUSKI EDWARD JOHN45 citations97
US8410051B2Apr 2, 2013
FGF21 mutants and uses thereof
BELOUSKI EDWARD JOHN63 citations97
US8188040B2May 29, 2012
FGF21 mutants and uses thereof
BELOUSKI EDWARD JOHN59 citations97
CUGENE INC
4 patentsUS11634467B2Apr 25, 2023
Cytokine-based bioactivatable drugs and methods of uses thereof
CUGENE INC3 citations71
US12319722B2Jun 3, 2025
Interleukin-15 (IL-15) fusion proteins and uses thereof
CUGENE INC0 citations61
US12319723B2Jun 3, 2025
Cytokine-based bioactivatable drugs and methods of uses thereof
CUGENE INC0 citations61
US12152060B2Nov 26, 2024
Interleukin-2 variants and methods of uses thereof
CUGENE INC1 citations61